![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Lowe C.
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.8, Iss.10, 1998-10, pp. : 1309-1322
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tumour necrosis factor antagonists
By Chantry D.
Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Safety of Tumour Necrosis Factor- Antagonists
By Khanna D. McMahon M. Furst D.E.
Drug Safety, Vol. 27, Iss. 5, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tumour necrosis factor antagonists: Hodgkin's lymphoma: 3 case reports
Reactions Weekly, Vol. 1, Iss. 1215, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)